This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Apolipoprotein E (apoE)

Authoring team

Apolipoprotein (apo) E was initially described as a lipid transport protein and major ligand for low density lipoprotein (LDL) receptors with a role in cholesterol metabolism and cardiovascular disease

  • apE has emerged as a major risk factor (causative gene) for Alzheimer's disease and other neurodegenerative disorders

  • the three isoforms (apoE2, apoE3, and apoE4), which differ by only a single amino acid interchange, has elucidated their unique functions
    • the apoE variants relate to different amino acids at positions 112 and 158: cysteine in both for apoE2, arginine at both sites for apoE4, and respectively cysteine and arginine for apoE3 that is viewed as the wild type

  • ApoE2 generally is most favourable and apoE4 least favourable for cardiovascular and neurological health (2)
    • however apoE2 homozygosity can precipitate type III hyperlipoproteinemia

Reference:

  1. Mahley RW.Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders.J Mol Med (Berl). 2016; 94: 739-746 .
  2. Marais AD. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. Pathology. 2019 Feb;51(2):165-176. doi: 10.1016/j.pathol.2018.11.002

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.